TAPUR
Phase 2 Recruiting
4,200 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
ProTarget
Phase 2 Recruiting
300 enrolled
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Phase 2 Completed
673 enrolled 22 charts
DRUP
Phase 2 Recruiting
1,550 enrolled
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
131 enrolled 11 charts